Last Updated: May 2026
Vilon is a synthetic dipeptide (Lys-Glu) from the Khavinson bioregulator family — the shortest peptide in the cluster — researched for immune system modulation, lifespan extension, and gene expression regulation. It is among the better-studied Khavinson bioregulators in terms of long-term rodent lifespan data and human cohort observation. Vilon is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.
Vilon is a synthetic Lys-Glu dipeptide — the shortest peptide in the Khavinson bioregulator cluster — proposed to enter cell nuclei and modulate gene expression in immune-related pathways. The dipeptide structure provides the most plausible case for nuclear entry given size constraints, and Vilon has been studied as a mechanistic reference compound for the broader bioregulator framework. The Lys-Glu sequence is a structural subset of the tripeptides Testagen and Vesugen (both Lys-Glu-Asp) and the tetrapeptide Pancragen (Lys-Glu-Asp-Trp). Evidence level: Preclinical (rodent lifespan extension, immune markers); Khavinson-group human cohort research; independent replication limited.
Preclinical rodent studies from the Khavinson group have reported lifespan extension of 24–42% in some models, reduced tumor incidence, and improved immune function markers in aging rodents. Human cohort studies, often in combination with other Khavinson bioregulators like Thymalin and Epithalon, have reported reduced all-cause mortality in elderly populations with 10–15 year follow-up — though these studies were non-blinded and originate predominantly from the Khavinson research group. Evidence level: Preclinical lifespan extension (rodent); Khavinson-group human cohort studies with long follow-up; independent replication limited.
Vilon is the shortest peptide in the Khavinson cluster (dipeptide) and the most mechanistically referenced for the nuclear-entry hypothesis given its size. It functions as the structural foundation for several longer Khavinson peptides that share the Lys-Glu core.
| Bioregulator | Structure | Length | Lys-Glu core | Lifespan data |
|---|---|---|---|---|
| Vilon | Dipeptide (Lys-Glu) | 2 AA | Yes (base) | 24–42% rodent extension reported |
| Testagen | Tripeptide (Lys-Glu-Asp) | 3 AA | Yes + Asp | Limited |
| Vesugen | Tripeptide (Lys-Glu-Asp) | 3 AA | Yes + Asp | Limited |
| Pancragen | Tetrapeptide (Lys-Glu-Asp-Trp) | 4 AA | Yes + Asp + Trp | Limited |
Side effects in available preclinical and human cohort data are mild — injection-site reactions are the most common report. The favorable safety profile is consistent with the broader Khavinson bioregulator class. Long-term safety has been observed in Khavinson human cohort studies over 10–15 years, with the caveats that apply to non-blinded research. Evidence level: Preclinical safety; Khavinson-group human cohort safety (long follow-up, non-blinded).
Vilon is not approved by the FDA, EMA, or any major Western regulator as of May 2026. Russian clinical research has been conducted. Regulatory context in FDA peptide regulation 2025–2026 timeline.
Vilon's dipeptide structure (Lys-Glu) is the shortest in the Khavinson cluster, making synthesis straightforward — but the small molecular weight (~275 Da) requires mass spectrometry identity confirmation appropriate to short peptides, where standard peptide-grade analytical methods may have less discrimination than for longer compounds. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.
Peptigrity purchases Vilon vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
Vilon is proposed to act on immune function and broad cellular aging through epigenetic gene-expression modulation, with preclinical rodent studies reporting lifespan extension of 24–42% and human cohort studies reporting reduced mortality in elderly populations. The human data is from non-blinded Khavinson-group research; FDA-grade Phase 2/3 efficacy has not been established.
No. Vilon is a synthesized Lys-Glu dipeptide; Thymalin is a polypeptide extract from bovine thymus tissue. Both target immune function but through different molecular forms — Vilon as a defined single-sequence dipeptide, Thymalin as a multi-component extract.
Vilon is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.
No active FDA approval pathway exists for Vilon as of May 2026.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW ~275 Da). COA interpretation in red flags in peptide certificates of analysis.
No. Vilon is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. Vilon is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.